High levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides are well-established risk factors for atherosclerotic cardiovascular disease, a leading cause of global mortality. Despite significant advancements in pharmaceutical treatments, many individuals struggle to achieve optimal lipid levels, often requiring lifelong medication regimens. Now, groundbreaking research into CRISPR gene editing offers a tantalizing glimpse into a future where a single intervention could provide durable lipid lowering.

The Promise of Gene Editing for Heart Health

At the heart of this innovative approach is angiopoietin-like 3 (ANGPTL3), a protein that plays a crucial role in lipid metabolism. Elevated ANGPTL3 levels contribute to higher circulating LDL-C and triglyceride concentrations. The new strategy leverages CRISPR base editing – a highly precise gene-editing technique that acts like a molecular scalpel, changing a single 'letter' of DNA at a specific target. By inactivating the gene responsible for ANGPTL3 production in the liver, researchers aim to sustainably reduce harmful lipid levels.

The experimental therapy involves a single infusion of guide RNA and messenger RNA (mRNA), encapsulated within a specialized GalNAc–lipid nanoparticle. This delivery system ensures the gene-editing components reach the liver, where ANGPTL3 is primarily produced, allowing for targeted and selective inactivation of the ANGPTL3 gene.

Early Success in the Lab and Beyond

Preclinical studies have yielded highly promising results. In human liver cells tested in vitro, the base editor successfully introduced the desired DNA change at the ANGPTL3 locus without detectable off-target editing at thousands of other potential sites, indicating a high level of precision and safety. Further studies in nonhuman primates demonstrated that a single dose of the treatment was well-tolerated and led to a remarkable average reduction of over 90% in circulating ANGPTL3 protein, with this effect confirmed to last for up to three years.

In animal models of hyperlipidemia (high lipid levels), including both mice and nonhuman primates, the targeted ANGPTL3 inactivation was associated with substantial reductions: approximately 40% to 50% in LDL-C and 50% to 70% in triglycerides. These significant and durable reductions underscore the potential of this approach to dramatically impact cardiovascular risk factors. The compelling preclinical data provided the scientific foundation for the initiation of an ongoing first-in-human clinical trial in patients with refractory hyperlipidemia syndromes, marking a critical step toward potential clinical application.

Key Takeaways

• CRISPR Base Editing: A precise gene-editing tool targeting the ANGPTL3 gene in the liver.

• Lipid Lowering: Preclinical studies showed significant (40-50% LDL-C, 50-70% triglycerides) and durable reductions.

• Single-Course Potential: Aims to offer a lasting solution for managing high lipids with one treatment.

• Safety Profile: No off-target editing detected in initial tests.

• Human Trials Underway: The therapy is currently being evaluated in human clinical trials.

The Global Angle

Cardiovascular diseases are a leading cause of morbidity and mortality worldwide, irrespective of economic status. The global burden of chronic conditions requiring ongoing medical management, like hyperlipidemia, strains healthcare systems in both developed and developing nations. A single-course, durable treatment for lipid lowering, if proven safe and effective in humans, could be transformative. It offers the potential to significantly reduce the need for daily medication adherence, minimize long-term healthcare costs associated with chronic disease management, and improve health outcomes across diverse populations, making advanced cardiovascular care more accessible and sustainable on a global scale.

This emerging therapy represents a paradigm shift from symptomatic management to addressing the underlying genetic drivers of disease, potentially offering a more fundamental and lasting solution to a pervasive global health challenge.

Source: Nature